Wyeth, GSK Adult Pneumococcal Vaccines Need More Serotypes For Approval
Manufacturers should design pneumococcal conjugate vaccines for adults with more serotypes to show non-inferiority to the currently marketed 23-valent polysaccharide vaccine, FDA's Vaccines & Related Biological Products Advisory Committee suggested at its Nov. 17 meeting
You may also be interested in...
Following on the multi-billion dollar success of Prevnar, Wyeth's vaccines unit is turning to a new generation of products to drive growth in 2009 and beyond
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011